前瞻性陈述内容 - 报告中部分非历史事实陈述为前瞻性陈述，涵盖公司分拆、财务运营表现、疫情影响、财务指标预测等内容[12] 投资风险 - 投资公司具有投机性或风险性，相关风险因素在“风险因素”部分有更详细描述[15] 业务和运营风险 - 业务和运营风险包括无法完成收购整合、缺乏额外资本、债务协议限制、重组活动不确定性等[18] 政府监管和诉讼风险 - 政府监管和诉讼相关风险涉及产品监管、合规问题、产品责任诉讼等[21] 分拆相关风险 - 分拆相关风险包括无法实现预期收益、税务问题、潜在赔偿责任等[21] 其他风险 - 其他风险有外汇汇率波动、原材料供应、竞争环境、税率变化等[21] 公司业务运营特点 - 公司依赖多种分销方式销售医疗设备产品[21] - 公司依赖多种分销方式销售医疗设备产品[21] 公司监管要求 - 公司产品需获得并维持监管批准和许可[21] - 产品受政府广泛监管，需获取和维持审批[21] 信息科技基础设施风险 - 公司信息科技基础设施可能面临服务中断、数据损坏、网络攻击等问题[21] 股权发行风险 - 公司发行额外普通股和优先股或转售受限普通股可能影响普通股市场价格[21] 外汇汇率风险 - 外汇汇率大幅波动可能损害公司财务业绩[21] 原材料供应风险 - 原材料、零部件供应及价格波动和短缺影响公司[21] 竞争环境风险 - 公司运营面临竞争环境挑战[21] 税率变化风险 - 税率变化或带来额外所得税负债[21] 产品安全与召回风险 - 产品存在安全问题或召回风险[21] 法规遵守风险 - 未能遵守产品制造相关法规存在风险[21] 产品营销风险 - 产品营销推广不当存在风险[21] 立法或监管改革风险 - 潜在立法或监管改革影响公司业务[21]

财务数据和关键指标变化 - 2022年第四季度销售增长5%,其中Recon业务增长14%,P&R业务增长低个位数 [13][20] - 2022年全年销售增长3.5%,Recon业务增长双位数,P&R业务增长3.5% [15][20] - 2022年第四季度毛利率提升190个基点,全年毛利率提升90个基点,主要得益于Recon业务占比提升和EGX系统带来的运营改善 [17][18] - 2022年第四季度EBITDA利润率为18.3%,全年EBITDA利润率提升70个基点 [17][19] 各条业务线数据和关键指标变化 Recon业务 - 2022年第四季度Recon业务增长14%,其中美国髋膝业务增长14%,四肢业务增长13% [14] - Recon业务毛利率持续提升,主要得益于创新产品EMPOWR Revision Knee和STAR Ankle的推出 [14] - 公司正在通过Mathys渠道将美国强势产品拓展至全球市场 [14] P&R业务 - 2022年第四季度P&R业务增长低个位数,全年增长3.5%,主要受到第三季度选择性手术放缓的滞后影响 [15] - 公司正在重塑P&R业务,目标是实现中单位数的持续增长,2022年创新活力从2018年接近0提升至双位数 [10][15] - 公司的MotionMD临床工作流解决方案增长30%,成为行业领先的解决方案 [15] 各个市场数据和关键指标变化 - 公司在美国和全球市场均实现了强劲增长,Recon业务在美国和全球市场均实现双位数增长 [14] - 公司在澳大利亚市场加强了业务布局,通过收购360 Med Care拓展了在该市场的业务 [12] 公司战略和发展方向及行业竞争 - 公司成功推出Enovis品牌,建立了由全球人才团队、EGX业务系统、创新引擎和强大资本结构支撑的医疗技术增长公司 [8] - 公司通过并购战略加速了增长,增强了创新能力并拓展了地理版图,过去几年的并购业务实现了双位数增长 [12] - 公司在Recon和P&R两大业务线均取得了良好进展,Recon业务保持了双位数增长,P&R业务正在重塑以实现中单位数的持续增长 [9][10] - 公司在2022年实现了25百万美元的固定成本削减,超出了原计划,为投资增长和应对工资通胀提供了空间 [12] 管理层对经营环境和未来前景的评论 - 管理层对2023年保持谨慎态度,预计Recon业务将保持双位数增长,P&R业务将温和改善 [22][38][45] - 管理层认为公司有能力保持Recon业务的双位数增长,并有信心P&R业务能够实现3%-5%的持续增长 [44][45] - 管理层表示公司有健康的并购机会管线,并有足够的资产负债表实力进行投资 [30][33][34] 问答环节重要的提问和回答 问题1 **Vik Chopra提问** 询问2023年EPS指引低于市场预期的原因 [28][29] **Phillip Berry回答** 解释EPS指引中对折旧、利息等因素的具体预测,整体上与市场预期基本一致 [29] 问题2 **Kyle Rose提问** 询问2023年收入和利润率的季度走势以及各业务线收入占比 [36][37][39] **Matthew Trerotola和Phillip Berry回答** 预计Recon业务将保持双位数增长,P&R业务增长存在一定不确定性,利润率的季度走势将与2022年类似 [37][38][39] 问题3 **Dane Reinhardt提问** 询问P&R业务短期压力的原因以及长期3%-5%增长目标的可信度 [43][44][45][46] **Matthew Trerotola回答** P&R业务受到选择性手术放缓的滞后影响,但公司有信心P&R业务能够实现3%-5%的持续增长 [44][45][46]

Recent Activity HSD Organic Revenue Growth Investing in Attractive Rehab/Recovery Modalities Rapidly Expanding High Growth & Margin Recon Platform • 3-5X market growth powered by Empowr3D® Knee and Taperfill® Hip Stem © 2023 Enovis Corporation 19 Expand Geographically Fill Product Line Gaps Expand Channels Apply Technology in Other Markets Enter Logical ClinicBased Adjacencies Expand along Continuum of Care Add Digital Solutions Build around Healthcare Provider Excel Win in the core Extend Build out from co ...

enovis. November 2, 2022 Third Quarter 2022 Financial Update © 2022 Enovis Corporation Forward-Looking Statement and Non-GAAP Disclaimer Forward-Looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, including the an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 Enovis Corporation | --- | --- | |----------------------------------------------------------------------------|----------------- ...

Enovis Corporation (NYSE:ENOV) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Derek Leckow - Vice President, Investor Relations Matt Trerotola - Chief Executive Officer Chris Hix - Executive Vice President & Chief Financial Officer Ben Berry - Interim Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Vik Chopra - Wells Fargo Matthew Mishan - KeyBanc Jason Wittes - Loop Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the ...

Letter to Our Shareholders May 2022 Q1 2022 Fellow Shareholders, During the first quarter of 2022 we achieved two very important milestones: 1) we produced advanced 3D Silicon™ lithium-ion batteries for customers from our first production line for customer qualification, and 2) we announced BrakeFlow™, a breakthrough in advanced lithium-ion battery safety. This critical innovation was possible due to our unique battery architecture, and we believe it puts considerable distance between us and any competitor ...

Enovis Corporation (NYSE:ENOV) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Christopher Hix - Executive Vice President & Chief Financial Officer Matthew Trerotola - Chief Executive Officer Conference Call Participants Jeff Johnson - Robert W. Baird & Co. Matthew Mishan - KeyBanc Capital Markets Vijay Kumar - Evercore ISI Josh Jennings - Cohen Operator Good day and thank you for standing by. Welcome to the Enovis First Quarter 2022 Earnings Conference Call. At this time, all ...

| --- | --- | --- | |--------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fourth Quarter 2021 | | | | | | | | Earnings Conference Call | | | | February 22, 2022 | | | | | | | | | | | | | | | | | | | | | | | Forward Looking Statement & Non-GAAP Disclaimer This presentation may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements ...

Colfax Corporation (CFX) Q4 2021 Earnings Conference Call February 22, 2022 8:00 AM ET Company Participants Matt Trerotola – President and Chief Executive Officer Shyam Kambeyanda – Executive Vice President and Chief Executive Officer (ESAB) Chris Hix – Executive Vice Preside and Chief Financial Officer Mike Macek – Vice President of Finance Conference Call Participants Scott Davis – Melius Research Chris Snyder – Union Bank of Switzerland Joseph Giordano – Cowen and Company Jeff Hammond – KeyBanc Capital M ...